Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $81.29 Average PT from Brokerages

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) have been given an average recommendation of "Buy" by the eight brokerages that are presently covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have covered the stock in the last year is $81.29.

A number of equities analysts recently issued reports on GPCR shares. HC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Structure Therapeutics in a report on Thursday, December 19th. Stifel Nicolaus started coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They set a "buy" rating and a $50.00 price target on the stock. JMP Securities reissued a "market outperform" rating and set a $91.00 price objective on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Finally, William Blair initiated coverage on Structure Therapeutics in a research report on Friday, February 28th. They set an "outperform" rating on the stock.

Structure Therapeutics Trading Down 3.4 %

GPCR stock traded down $0.71 on Tuesday, hitting $20.34. The company had a trading volume of 736,006 shares, compared to its average volume of 836,388. Structure Therapeutics has a 12-month low of $19.39 and a 12-month high of $62.74. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -27.49 and a beta of -2.37. The stock's 50-day simple moving average is $24.71 and its 200 day simple moving average is $31.63.

Remove Ads

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. Research analysts forecast that Structure Therapeutics will post -0.82 earnings per share for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Several large investors have recently made changes to their positions in the business. Geode Capital Management LLC increased its holdings in Structure Therapeutics by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 45,225 shares of the company's stock valued at $1,985,000 after acquiring an additional 312 shares during the last quarter. Virtus ETF Advisers LLC increased its holdings in shares of Structure Therapeutics by 25.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after purchasing an additional 455 shares during the last quarter. ANTIPODES PARTNERS Ltd increased its holdings in shares of Structure Therapeutics by 115.0% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after purchasing an additional 553 shares during the last quarter. LPL Financial LLC lifted its position in shares of Structure Therapeutics by 6.0% in the fourth quarter. LPL Financial LLC now owns 11,485 shares of the company's stock worth $311,000 after buying an additional 646 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its stake in Structure Therapeutics by 12.9% during the fourth quarter. Envestnet Asset Management Inc. now owns 7,403 shares of the company's stock valued at $201,000 after buying an additional 843 shares during the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.